Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Up 1.8% - Here's Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO - Get Free Report) was up 1.8% during mid-day trading on Wednesday . The stock traded as high as GBX 370 ($4.55) and last traded at GBX 363.80 ($4.47). Approximately 11,207 shares traded hands during mid-day trading, an increase of 27% from the average daily volume of 8,834 shares. The stock had previously closed at GBX 357.50 ($4.39).

Hemogenyx Pharmaceuticals Stock Down 0.7 %

The stock's 50 day moving average is GBX 273.12 and its 200 day moving average is GBX 97.04. The company has a market capitalization of £4.85 billion, a PE ratio of -36,200.00 and a beta of 3.14. The company has a debt-to-equity ratio of 92.09, a quick ratio of 6.72 and a current ratio of 4.38.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.